The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
The FDA is moving to remove GLP-1 medications from the 503B Compounding Bulks List, a regulatory step that could significantly limit access to compounded versions of semaglutide and tirzepatide. This article explains what the 503B designation means, why it matters to patients, and what your options are going forward.
Eli Lilly's Mounjaro (tirzepatide) has surpassed Merck's Keytruda to become the world's top-selling drug, a milestone that signals a dramatic shift in how medicine treats obesity and type 2 diabetes. For patients researching GLP-1 medications, this news carries real implications for supply, pricing, and access. Here is what you need to know.
The FDA's recent action on compounded semaglutide is shaking up telehealth GLP-1 providers, and altRx is no exception. This review covers what altRx is offering in 2026, how their pricing and refund policy stack up, and what patients need to know before signing up or switching providers.
A new blood test developed by Hepta Bio may be able to predict how well a patient will respond to GLP-1 medications before they ever take a dose. This could change how doctors prescribe semaglutide and tirzepatide, and potentially save patients significant time and money. Here's what you need to know.
Wegovy sales are breaking records and Novo Nordisk is reporting major profit highs driven by semaglutide demand. For patients already on GLP-1 medications or considering starting, surging sales have real implications for pricing, insurance coverage, and access. Here's what you need to know.
An oral version of semaglutide is drawing attention from patients who want the benefits of GLP-1 therapy without weekly injections. This guide breaks down how the Ozempic pill works, how it compares to the injectable, and what to consider before switching or starting.
Novo Nordisk has made oral versions of its semaglutide medications available through Amazon with same-day delivery in select areas. This shift could change how patients access GLP-1 therapy, but there are important details on cost, eligibility, and safety to understand before ordering.
Several states are revising their employee health benefit rules around GLP-1 medications like semaglutide and tirzepatide for weight loss. If you're a state employee or on a government health plan, these changes could affect your out-of-pocket costs and access. Here's what you need to know.